Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.
Montefiori
D C
DC
Center for AIDS Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. monte005@mc.duke.edu
Evans
T G
TG
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D003429:Cross Reactions; D015686:Gene Products, env / Q000737:chemistry / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000276:immunology; D015497:HIV-1 / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007116:Immunization, Passive; D009500:Neutralization Tests; D054299:env Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1